Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. PURCHASE AND SALE AGREEMENT BY AND BETWEEN OPHTHOTECH CORPORATION AND NOVO A/S EFFECTIVE AS OF May 23, 2013Purchase and Sale Agreement • July 15th, 2013 • Ophthotech Corp. • Pharmaceutical preparations • New York
In a large, randomized, controlled Phase 2b study reported last year, Fovista in combination with Lucentis® (ranibizumab injection) demonstrated superior efficacy over Lucentis monotherapy in patients with wet AMD. Patients receiving the combination of Fovista (1.5 mg) and Lucentis gained a mean of 10.6 letters of vision on the ETDRS standardized chart at 24 weeks, compared to 6.5 letters for patients receiving Lucentis monotherapy (p=0.019), representing a 62% additional benefit. No significant safety issues were observed for either treatment group in the trial.
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • July 15th, 2013 • Ophthotech Corp. • Pharmaceutical preparations • Massachusetts
If at the time any given milestone payment set forth in Section 4.3.1 is due, one or more preceding milestone payments for logically antecedent milestones have not been paid, then such unpaid antecedent milestone payments shall be paid at such time as well. For example, if milestone (d) is achieved, but milestone (c) was never achieved or paid, the payments for milestones (c) and (d) shall be made concurrently. For the avoidance of doubt, in no event shall any of the foregoing milestones be paid more than once for any Anti-PDGF Aptamer, even if such Anti-PDGF Aptamer is approved or utilized for different Indications than first approved or utilized.
THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • July 15th, 2013 • Ophthotech Corp. • Pharmaceutical preparations • New York
THIS THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (“Agreement”) is made as of May 23, 2013, by and among Ophthotech Corporation, a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”, and any additional Investor that becomes a party to this Agreement in accordance with Section 6.9 hereof.
